Hainan Poly Pharm Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Min Hua Fan

Algemeen directeur

CN¥769.8k

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	12.1yrs
Eigendom CEO	39.9%
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	6.2yrs

Recente managementupdates

Recent updates

What Hainan Poly Pharm. Co., Ltd's (SZSE:300630) 46% Share Price Gain Is Not Telling You

Oct 08

Hainan Poly Pharm. Co., Ltd (SZSE:300630) Stocks Shoot Up 28% But Its P/E Still Looks Reasonable

Aug 16

It's Down 27% But Hainan Poly Pharm. Co., Ltd (SZSE:300630) Could Be Riskier Than It Looks

Apr 21

A Piece Of The Puzzle Missing From Hainan Poly Pharm. Co., Ltd's (SZSE:300630) 27% Share Price Climb

Mar 06

CEO

Min Hua Fan (63 yo)

12.1yrs

Tenure

CN¥769,800

Compensatie

Ms. Min Hua Fan is Chairman & General Manager of Hainan Poly Pharm. Co., Ltd from October 30, 2012.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Min Hua Fan	Chairman & GM	12.1yrs	CN¥769.80k	39.92% CN¥ 1.8b
Tong Ning Luo	CFO, Deputy GM & Non-Independent Director	2.9yrs	CN¥583.00k	0.041% CN¥ 1.9m
Zhou Mao	Deputy GM	12.1yrs	CN¥590.20k	0.23% CN¥ 10.8m
Shuge Jiao	Non-Independent Director	9.4yrs	geen gegevens	geen gegevens
Ji Ping Wang	Non-Employee Supervisor	12.1yrs	geen gegevens	geen gegevens
Hui Fang Xie	Employee Representative to the Supervisory Board	12.1yrs	geen gegevens	0.000020% CN¥ 925.8
Dezhu Fan	Independent Director	2.9yrs	CN¥60.00k	0.00049% CN¥ 22.7k
Yu Ding	Chairman of Supervisory Board	2.9yrs	geen gegevens	geen gegevens
Yadong Chen	Independent Director	2.9yrs	CN¥60.00k	geen gegevens
Lei Pan	Independent Director	2.9yrs	CN¥60.00k	geen gegevens

6.2yrs

Gemiddelde duur

52.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 300630 wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.2 jaar).

Hainan Poly Pharm Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Hainan Poly Pharm. Co., Ltd, Annual General Meeting, Aug 23, 2024

Hainan Poly Pharm. Co., Ltd, Annual General Meeting, Aug 23, 2024

High number of new directors

High number of new directors

High number of new directors

Recent updates

Third quarter 2024 earnings released: CN¥0.089 loss per share (vs CN¥0.31 profit in 3Q 2023)

What Hainan Poly Pharm. Co., Ltd's (SZSE:300630) 46% Share Price Gain Is Not Telling You

Hainan Poly Pharm. Co., Ltd to Report Q3, 2024 Results on Oct 28, 2024

Second quarter 2024 earnings released: CN¥0.29 loss per share (vs CN¥0.30 profit in 2Q 2023)

Investor sentiment improves as stock rises 30%

Hainan Poly Pharm. Co., Ltd (SZSE:300630) Stocks Shoot Up 28% But Its P/E Still Looks Reasonable

Hainan Poly Pharm. Co., Ltd, Annual General Meeting, Aug 23, 2024

Hainan Poly Pharm. Co., Ltd, Annual General Meeting, Aug 23, 2024

Investor sentiment improves as stock rises 21%

Investor sentiment deteriorates as stock falls 36%

First quarter 2024 earnings released: EPS: CN¥0.15 (vs CN¥0.32 in 1Q 2023)

High number of new directors

Hainan Poly Pharm. Co., Ltd to Report First Half, 2024 Results on Aug 29, 2024

New minor risk - Financial data availability

Investor sentiment deteriorates as stock falls 16%

It's Down 27% But Hainan Poly Pharm. Co., Ltd (SZSE:300630) Could Be Riskier Than It Looks

Investor sentiment deteriorates as stock falls 15%

Hainan Poly Pharm. Co., Ltd to Report Q1, 2024 Results on Apr 25, 2024

A Piece Of The Puzzle Missing From Hainan Poly Pharm. Co., Ltd's (SZSE:300630) 27% Share Price Climb

Investor sentiment deteriorates as stock falls 15%

Hainan Poly Pharm. Co., Ltd to Report Fiscal Year 2023 Results on Apr 20, 2024

Hainan Poly Pharm. Co., Ltd(SZSE:300630) dropped from Shenzhen Stock Exchange Component Index

New minor risk - Shareholder dilution

Investor sentiment improves as stock rises 56%

New minor risk - Earnings quality

New major risk - Share price stability

New major risk - Financial position

Third quarter 2023 earnings released: EPS: CN¥0.31 (vs CN¥0.38 in 3Q 2022)

Hainan Poly Pharm. Co., Ltd to Report Q3, 2023 Results on Oct 25, 2023

Second quarter 2023 earnings released: EPS: CN¥0.30 (vs CN¥0.29 in 2Q 2022)

Investor sentiment improves as stock rises 18%

Hainan Poly Pharm. Co., Ltd Announces Dividend Implementation of Cash Dividend for 2022, Payable on 18 July 2023

First quarter 2023 earnings released: EPS: CN¥0.32 (vs CN¥0.37 in 1Q 2022)

Investor sentiment deteriorates as stock falls 17%

High number of new directors

Third quarter 2022 earnings released: EPS: CN¥0.38 (vs CN¥0.37 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.29 (vs CN¥0.29 in 2Q 2021)

Hainan Poly Pharm. Co., Ltd Announces 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on July 13, 2022

Investor sentiment improved over the past week

Hainan Poly Pharm. Co., Ltd Approves Cash Dividend for the Year 2021

Hainan Poly Pharm. Co.,Ltd Proposes Profit Distribution for 2021

High number of new directors

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorated over the past week

Hainan Poly Pharm. Co., Ltd. (SZSE:300630) announces an Equity Buyback for CNY 10 million worth of its shares.

Third quarter 2021 earnings released: EPS CN¥0.37 (vs CN¥0.29 in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.29 (vs CN¥0.18 in 2Q 2020)

Hainan Poly Pharm. Co., Ltd. Approves Profit Distribution Proposal for 2020

Hainan Poly Pharm. Co., Ltd. Announces Final Dividend for the Year 2020

Full year 2020 earnings released: EPS CN¥0.94 (vs CN¥0.72 in FY 2019)

New 90-day high: CN¥49.28

New 90-day high: CN¥47.61

New 90-day low: CN¥38.94

Third quarter earnings released

Market bids up stock over the past week

New 90-day low: CN¥40.41

First half earnings released

Hainan Poly Pharm. Co., Ltd. to Report First Half, 2020 Results on Aug 27, 2020

Hainan Poly Pharm. Co., Ltd. announced a financing transaction

CEO

Tenure

Compensatie

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd